| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20020555 | HPV | ENSG00000180616.9 | protein_coding | SSTR2 | No | No | 6752 | P30874 |
| TVIS20020556 | HPV | ENSG00000180616.9 | protein_coding | SSTR2 | No | No | 6752 | P30874 |
| TVIS44018052 | HTLV-1 | ENSG00000180616.9 | protein_coding | SSTR2 | No | No | 6752 | P30874 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | SSTR2 |
|---|---|
| DrugBank ID | DB06791 |
| Drug Name | Lanreotide |
| Target ID | BE0003528 |
| UniProt ID | P30874 |
| Regulation Type | agonist |
| PubMed IDs | 26416534 |
| Citations | Buil-Bruna N, Garrido MJ, Dehez M, Manon A, Nguyen TX, Gomez-Panzani EL, Troconiz IF: Population Pharmacokinetic Analysis of Lanreotide Autogel((R))/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials. Clin Pharmacokinet. 2016 Apr;55(4):461-73. doi: 10.1007/s40262-015-0329-4. |
| Groups | Approved |
| Direct Classification | Oligopeptides |
| SMILES | [H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H] |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL1201185 |
